Janssen Research & Development: Careers Related Stories Cracking the Genetic Code: Why Gene Sequencing May Hold the Key to Intercepting Diseases Before They Start Can Artificial Intelligence Change How We Discover New Medicines? The World Is Our Lab: A Collaborative Approach to Research & Development...
Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and one of the world’s leaders in oncology, is focused on harnessing the most compelling science with the aim of intercepting, preventing, treating, and ultimately curing cancer. Working toward t...
See the innovative ideas that help transform healthcare, and how Janssen research and development hopes to make further advancements in medicine.
近日,生物制药公司Janssen Research&Development宣布,美国FDA已授予其在研抗抑郁新药esketamine突破性疗法认定,适用于有自杀倾向的重度抑郁症(Major depression disorder)。如果最终获得FDA批准,esketamine将是近50年来治疗重度抑郁症的第一个新药。 抑郁症是一种在全世界范围内常见的精神疾患,估计共有3.5亿名患者,遍布各个...
New research based on real‐world data presented at the American Psychiatric Association''s annual meeting May 18–22 in San Francisco found a need to increase and improve interventions to deliver better outcomes for adults with major depressive disorder (MDD) or who have been diagnosed with ...
Originator Janssen Research & Development Developer Janssen Research & Development; Minerva Neurosciences Class Antidepressants; Fluorinated hydrocarbons; Ketones; Pyrimidines; Pyrroles; Sleep disorder therapies; Small molecules; Triazoles Mechanism of Action Orexin receptor type 2 antagonists Orphan Drug ...
Global Head of Janssen Research & Development. “By advancing science in these areas, our new research platforms will strive to deliver the next generation of transformational medical innovation. We believe the positive impact on people, communities, governments, medicine and the global economy will ...
今天,生物制药公司Janssen Research & Development 宣布,美国FDA已授予其在研抗抑郁新药 esketamine 突破性疗法认定,适用于有自杀倾向的重度抑郁症(Major depression disorder)。如果最终获得FDA批准,esketamine 将是近50年来治疗重度抑郁症的第一个新药。 抑郁症是一种在全世界范围内常见的精神疾患,估计共有3.5亿名患者...
今天,生物制药公司Janssen Research & Development宣布,美国FDA已授予其在研抗抑郁新药esketamine突破性疗法认定,适用于有自杀倾向的重度抑郁症(Major depression disorder)。如果最终获得FDA批准,esketamine将是近50年来治疗重度抑郁症的第一个新药。 抑郁症是一种在全世界范围内常见的精神疾患,估计共有3.5亿名患者,遍布...
(Janssen Research & Development, LLC) Talquetamab是一款first-in-class现货型双特异性T细胞结合抗体,能同时靶向MM细胞上的GPRC5D和T细胞上的CD3,是继BCMA的Tecvayli之后,第二个用于多发性骨髓瘤的双特异性抗体。于2023年 8 月获 FDA 加速批准上市,其获批基于一项 I/II 期 MonumenTAL-1 临床试验的结果。结果...